Stock listing
NASDAQ:UPB Upstream Bio, Inc. Stock
Home listing (NASDAQ) of Upstream Bio, Inc.
Follow Upstream Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:UPB
$1.59 USD -0.41 (-20.5%)
Close on Nov 20, 2026
- Day range
- $1.56 – $2.06 USDNov 20, 2026
- Volume
- 1.39M sharesNov 20, 2026
- Market cap
- $87.15M USDAt the close on Nov 20, 2026 · price × 54.81M shares outstanding
- 52-week range
- $1.56 – $33.68 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.95M USDMedian day 947,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:UPB · Home | $1.59 USD | -0.41 (-20.5%) | 1,386,100 | $1.98 | $2.06 | $1.56 | $2.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:UPB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.59 | -0.41 | -20.5% | $1.98 | $2.06 | $1.56 | 1,386,100 | |
| $2.00 | -0.08 | -3.8% | $2.09 | $2.19 | $2.00 | 856,100 | |
| $2.08 | -0.02 | -1.0% | $2.16 | $2.19 | $2.05 | 1,239,200 | |
| $2.10 | -0.05 | -2.3% | $2.10 | $2.205 | $2.005 | 1,182,800 | |
| $2.15 | -0.63 | -22.7% | $2.82 | $2.83 | $2.12 | 1,993,300 | |
| $2.78 | -0.08 | -2.8% | $2.86 | $2.98 | $2.73 | 891,300 | |
| $2.86 | -0.34 | -10.6% | $3.13 | $3.13 | $2.80 | 2,528,600 | |
| $3.20 | -0.18 | -5.3% | $3.38 | $3.46 | $3.13 | 1,318,100 | |
| $3.38 | -0.20 | -5.6% | $3.52 | $3.655 | $3.24 | 1,175,000 | |
| $3.58 | +0.35 | +10.8% | $3.23 | $3.595 | $3.17 | 1,983,600 | |
| $3.23 | +0.02 | +0.6% | $3.24 | $3.28 | $3.02 | 1,139,900 | |
| $3.21 | -0.49 | -13.2% | $3.64 | $3.675 | $3.00 | 1,064,600 | |
| $3.70 | +0.31 | +9.1% | $3.59 | $3.843 | $3.52 | 1,246,900 | |
| $3.39 | +0.04 | +1.2% | $3.36 | $3.525 | $3.305 | 978,500 | |
| $3.35 | -0.06 | -1.8% | $3.42 | $3.46 | $3.16 | 936,100 | |
| $3.41 | +0.14 | +4.3% | $3.26 | $3.425 | $3.15 | 946,100 | |
| $3.27 | +0.29 | +9.7% | $3.00 | $3.32 | $2.97 | 1,178,800 | |
| $2.98 | +0.19 | +6.8% | $2.78 | $2.99 | $2.68 | 1,323,100 | |
| $2.79 | +0.04 | +1.5% | $2.76 | $2.935 | $2.68 | 1,179,600 | |
| $2.75 | +0.01 | +0.4% | $2.75 | $2.97 | $2.72 | 983,800 | |
| $2.74 | -0.25 | -8.4% | $2.95 | $2.96 | $2.695 | 1,051,200 | |
| $2.99 | +0.19 | +6.8% | $2.77 | $2.99 | $2.70 | 1,450,000 | |
| $2.80 | -0.02 | -0.7% | $2.83 | $2.975 | $2.765 | 1,410,500 | |
| $2.82 | +0.02 | +0.7% | $2.79 | $3.09 | $2.78 | 1,676,000 | |
| $2.80 | +0.04 | +1.4% | $2.76 | $3.07 | $2.75 | 1,603,700 | |
| $2.76 | -0.61 | -18.1% | $3.39 | $3.39 | $2.74 | 1,836,400 | |
| $3.37 | -0.05 | -1.5% | $3.44 | $3.555 | $3.285 | 1,285,300 | |
| $3.42 | -0.13 | -3.7% | $3.475 | $3.60 | $3.29 | 1,572,500 | |
| $3.55 | -0.62 | -14.9% | $4.14 | $4.155 | $3.52 | 1,037,400 | |
| $4.17 | -0.53 | -11.3% | $4.68 | $4.72 | $4.12 | 848,400 | |
| $4.70 | +0.15 | +3.3% | $4.54 | $4.76 | $4.51 | 1,187,800 | |
| $4.55 | -0.06 | -1.3% | $4.53 | $4.65 | $4.365 | 2,857,200 | |
| $4.61 | +0.02 | +0.4% | $4.55 | $4.72 | $4.50 | 908,400 | |
| $4.59 | -0.26 | -5.4% | $4.84 | $4.865 | $4.53 | 1,062,300 | |
| $4.85 | -0.19 | -3.8% | $5.07 | $5.10 | $4.665 | 1,010,600 | |
| $5.04 | 0.00 | 0.0% | $5.12 | $5.21 | $4.86 | 956,500 | |
| $5.04 | -0.23 | -4.4% | $5.25 | $5.345 | $4.98 | 832,400 | |
| $5.27 | +0.08 | +1.5% | $5.23 | $5.455 | $5.145 | 851,200 | |
| $5.19 | -0.11 | -2.1% | $5.28 | $5.305 | $4.99 | 784,200 | |
| $5.30 | -0.06 | -1.1% | $5.34 | $5.385 | $5.12 | 615,400 | |
| $5.36 | +0.19 | +3.7% | $5.20 | $5.39 | $5.07 | 429,200 | |
| $5.17 | -0.02 | -0.4% | $5.19 | $5.20 | $5.045 | 566,600 | |
| $5.19 | -0.30 | -5.5% | $5.48 | $5.49 | $4.985 | 553,000 | |
| $5.49 | +0.125 | +2.3% | $5.44 | $5.56 | $5.38 | 360,400 | |
| $5.365 | +0.025 | +0.5% | $5.42 | $5.44 | $5.27 | 364,000 | |
| $5.34 | +0.03 | +0.6% | $5.32 | $5.41 | $5.21 | 1,001,000 | |
| $5.31 | -0.02 | -0.4% | $5.44 | $5.48 | $5.235 | 533,900 | |
| $5.33 | -0.15 | -2.7% | $5.49 | $5.54 | $5.27 | 497,200 | |
| $5.48 | -0.33 | -5.7% | $5.81 | $5.81 | $5.455 | 421,300 | |
| $5.81 | +0.08 | +1.4% | $5.75 | $5.87 | $5.70 | 491,000 | |
| $5.73 | -0.02 | -0.3% | $5.84 | $5.84 | $5.65 | 501,300 | |
| $5.75 | -0.21 | -3.5% | $5.86 | $5.86 | $5.67 | 562,400 | |
| $5.96 | -0.23 | -3.7% | $6.14 | $6.20 | $5.77 | 726,200 | |
| $6.19 | +0.18 | +3.0% | $6.01 | $6.21 | $5.77 | 949,700 | |
| $6.01 | -0.07 | -1.2% | $6.00 | $6.23 | $5.965 | 642,900 | |
| $6.08 | -0.40 | -6.2% | $6.49 | $6.49 | $5.77 | 1,351,800 | |
| $6.48 | -0.07 | -1.1% | $6.62 | $6.98 | $6.41 | 515,400 | |
| $6.55 | -0.07 | -1.1% | $6.58 | $6.72 | $6.50 | 476,500 | |
| $6.62 | -0.07 | -1.0% | $6.64 | $6.77 | $6.44 | 895,000 | |
| $6.69 | -0.10 | -1.5% | $6.71 | $6.79 | $6.60 | 445,500 | |
| $6.79 | -0.34 | -4.8% | $7.11 | $7.14 | $6.78 | 335,100 | |
| $7.13 | -0.05 | -0.7% | $7.18 | $7.31 | $6.90 | 432,900 | |
| $7.18 | +0.57 | +8.6% | $6.68 | $7.18 | $6.55 | 554,420 | |
| $6.61 | -0.36 | -5.2% | $7.00 | $7.11 | $6.46 | 538,545 | |
| $6.97 | +0.12 | +1.8% | $6.91 | $7.006 | $6.85 | 434,200 | |
| $6.85 | -0.665 | -8.8% | $7.48 | $7.555 | $6.745 | 592,900 |
- Ticker
- NASDAQ:UPB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
Latest deck · Sep 8, 2026
Investor Presentation (September 2026)
Investor deck · 26 slides
Latest news
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
Nov 10, 2026
Closed $3.38 (-5.6%) on Nov 10, 2026
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
Aug 11, 2026
Closed $7.09 (-4.7%) on Aug 11, 2026
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
Jun 14, 2026
Closed $6.10 (0.0%) on Jun 15, 2026
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Jun 8, 2026
Closed $6.45 (-8.5%) on Jun 8, 2026
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Jun 3, 2026
Closed $7.63 (+5.2%) on Jun 3, 2026
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
May 18, 2026
Closed $8.51 (-6.4%) on May 18, 2026
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
Closed $9.36 (+4.6%) on May 13, 2026
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Apr 17, 2026
Closed $9.99 (-1.1%) on Apr 17, 2026
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 26, 2026
Closed $9.79 (+3.4%) on Mar 26, 2026
Upstream Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 38 in all · newest Nov 10, 2026 · oldest 2024
- Decks
- 6 decks · latest Sep 8, 2026
Where Upstream Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:UPB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:UPB | BOATS | United States | USD |
Valuation
EV/sales −41.6× against a median of 30.3×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$119.4M USD
- P/E
- Loss
- EV/sales
- −41.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- 98.3%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.95
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Upstream Bio, Inc. · NASDAQ:UPB | US$87.15M | −US$119.4M | n/a | −41.6× | n/a | 0.4× | n/a | 0.0× | 1.95 |
| Infant Bacterial Therapeutics AB Class B · OMXSTO:IBT_B | US$88.36M | US$77.74M | n/a | n/a | n/a | 17.0× | n/a | 0.0× | n/a |
| Y-Biologics Inc. · KRX:338840 | US$88.10M | US$71.36M | n/a | 30.1× | n/a | 6.8× | n/a | 0.9× | n/a |
| Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX | US$87.57M | US$11.59M | 1.3× | 0.5× | n/a | 1.2× | 273.7% | 0.1× | 0.72 |
| Retension Pharmaceuticals, Inc. · NASDAQ:RTSN | US$87.57M | US$78.38M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Equillium, Inc. · NASDAQ:EQ | US$87.26M | US$34.71M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.31 |
| Senhwa Biosciences Inc · TPEX:6492 | US$86.77M | US$67.44M | n/a | 2,117× | n/a | 4.6× | n/a | 0.0× | n/a |
| Bioceltix SA · GPW:BCX | US$86.38M | US$72.43M | n/a | n/a | n/a | 5.6× | n/a | 0.0× | n/a |
| Perspective Therapeutics, Inc. · AMEX:CATX | US$86.05M | −US$114.1M | n/a | −570× | n/a | 0.3× | n/a | 0.0× | 1.47 |
| Pharmosa Biopharm Inc. · TPEX:6875 | US$86.04M | US$62.27M | n/a | 38.5× | n/a | 2.1× | −658.1% | 0.1× | n/a |
| Formosa Pharmaceuticals, Inc. · TWSE:6838 | US$85.43M | US$48.52M | n/a | 30.4× | n/a | 2.0× | −361.4% | 0.0× | n/a |
| Median of the others | US$87.02M | US$64.86M | 1.3× | 30.3× | 2.1× | −361.4% | 0.0× | 1.31 |
Forecasts
5 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 24.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.93 · 8 analysts
- Revenue, year to Dec 2026
- 2.59M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Rand Sutherland | Chief Executive Officer |
| Mike Gray | Chief Financial Officer and Chief Operating Officer |
| Allison Ambrose | General Counsel |
| Meggan Buckwell | Director, Corporate Communications and Investor Relations |
| Amy Iannelli | Vice President, Finance |
| Ashish Kalra | Vice President, Translational Research |
| Christopher Silva | Vice President, Supply Chain |
| Edd Fleming | Executive Vice President, Enavate Sciences |
| Ken Adams | Senior Vice President, Clinical Operations & Medical Writing |
| Marie Sanchirico | Vice President, Medical Affairs |
| Mersedeh Miraliakbari | Senior Vice President, Regulatory Affairs and Quality |
| Parika Petaipimol | Vice President, Technical Operations |
| Sumathi Sivapalasingam | Vice President & Head of Clinical Development |
| Aaron Deykin | Chief Medical Officer & Head of R&D |
| Adam Houghton | Chief Business Officer |
| Liam Ratcliffe | Head of Biotechnology, Access Industries |
| Marcella K. Ruddy | Chief Medical Officer, Tectonic Therapeutic |
| Stacy Price | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Ron Renaud | Chair, Board of Directors |
| Daniella Beckman | Member, Board of Directors |
| Edd Fleming | Executive Vice President, Enavate Sciences |
| Liam Ratcliffe | Head of Biotechnology, Access Industries |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −5.6% |
| Q2 2026 | Aug 11, 2026 · Before open | −4.7% |
| Q1 2026 | May 13, 2026 · Before open | +4.6% |
| Q4 2025 | Mar 24, 2026 · Before open | 0.0% |
| Q3 2025 | Nov 5, 2025 · Before open | −4.3% |
| Q2 2025 | Aug 6, 2025 · Before open | +7.9% |
| Q1 2025 | May 6, 2025 · Before open | −5.4% |
| Q4 2024 | Mar 12, 2025 | +5.8% |
| Q3 2024 | Nov 7, 2024 · Before open | +1.7% |
| Q2 2024 | Aug 28, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 26 slides | Sep 8, 2026 |
| Technical Presentation (September 2026) | Technical | 11 slides | September 2026 |
| Technical Presentation (February 2026) | Technical | 19 slides | Feb 11, 2026 |
| Technical Presentation (September 2025) | Technical | 25 slides | Sep 2, 2025 |
| European Respiratory Society (ERS) Congress 2025 | Conference | 9 slides | September 2025 |
| Investor Presentation (May 2025) | Investor deck | 30 slides | May 2025 |
IPO
Priced at US$17.00 a share on Oct 10, 2024.
- Price
- US$17.00 a share
- Shares offered
- 15,000,000 shares of common stock
- Offering size
- US$255 million
- Underwriters' option
- Up to 2,250,000 more shares
- Underwriters
- J.P. Morgan, TD Cowen, Piper Sandler, William Blair · In the order on the cover
- Shares delivered
- On or about Oct 15, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 12, 2024 |
| Filed publicly | Sep 18, 2024 |
| Amended once | Oct 7, 2024 |
| Shares registered with an exchange | Oct 8, 2024 |
| Declared effective by the SEC | Oct 10, 2024 |
| Final prospectus, with the price | Oct 11, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 11, 2024 |
| EFFECT · Notice that a registration is effective | Oct 10, 2024 |
| S-1MEF · Registration of more shares for the same offering | Oct 10, 2024 |
| CERT · Exchange's certificate of listing | Oct 10, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 8, 2024 |
| CORRESP · Letter to the SEC | Oct 8, 2024 |
| CORRESP · Letter to the SEC | Oct 8, 2024 |
| S-1/A · Registration statement, amended | Oct 7, 2024 |
| CORRESP · Letter to the SEC | Sep 30, 2024 |
| CORRESP · Letter to the SEC | Sep 18, 2024 |
All 19 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Sep 18, 2024 |
| UPLOAD · Letter from the SEC | Aug 20, 2024 |
| DRSLTR · Letter to the SEC with a draft | Aug 9, 2024 |
| DRS/A · Draft registration statement, amended | Aug 9, 2024 |
| UPLOAD · Letter from the SEC | Jul 25, 2024 |
| DRSLTR · Letter to the SEC with a draft | Jul 18, 2024 |
| DRS/A · Draft registration statement, amended | Jul 18, 2024 |
| UPLOAD · Letter from the SEC | Jul 9, 2024 |
| DRS · Draft registration statement | Jun 12, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 11, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 2.85M | 2.37M | 2.38M | 1.21M |
| Cost of revenue | 188.0K | 89.0K | 60.0K | 7.00K |
| Gross profit | 2.85M | 2.37M | 2.38M | 1.21M |
| Research and development | 136.8M | 63.0M | 31.8M | 18.7M |
| Selling, general and administrative | 26.4M | 17.2M | 10.7M | 6.46M |
| Operating income | -160.4M | -77.8M | -40.1M | -23.9M |
| Depreciation and amortization | 188.0K | 89.0K | 60.0K | 7.00K |
| EBITDA | -160.2M | -77.7M | -40.1M | -23.9M |
| Income before tax | -143.4M | -62.8M | -20.5M | -23.9M |
| Income tax | 0 | 0 | 0 | |
| Net income | -143.4M | -62.8M | -20.5M | -23.9M |
| Earnings per share, basic | -2.66 | -5.58 | -12.95 | -0.66 |
| Earnings per share, diluted | -2.66 | -5.58 | -12.95 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 101.6M | 325.9M | 25.8M | 17.1M |
| Short-term investments | 239.9M | 144.6M | 84.0M | 0 |
| Receivables | 668.0K | 613.0K | 98.0K | 412.0K |
| Current assets | 351.8M | 479.2M | 117.0M | 18.3M |
| Property, plant and equipment | 559.0K | 582.0K | 159.0K | |
| Goodwill | 0 | |||
| Total assets | 353.8M | 481.7M | 117.2M | 18.5M |
| Accounts payable | 2.73M | 4.04M | 1.99M | 712.0K |
| Current liabilities | 13.5M | 10.7M | 6.51M | 4.86M |
| Total debt | 1.27M | 1.83M | 45.0K | 94.0K |
| Total liabilities | 14.0M | 11.9M | 9.39M | 124.6M |
| Shareholders' equity | 339.8M | 469.9M | -123.1M | -106.2M |
| Shares outstanding | 54.2M | 53.6M | 2.99M | 36.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -133.3M | -59.2M | -37.9M | -19.0M |
| Capital spending | -165.0K | -511.0K | -144.0K | -82.0K |
| Free cash flow | -133.4M | -59.7M | -38.1M | -19.1M |
| Cash from investing | -93.5M | -59.5M | -82.8M | -82.0K |
| Cash from financing | 2.44M | 418.9M | 129.6M | 9.96M |
| Change in cash | -224.3M | 300.3M | 8.78M | -9.14M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 1, 2026 | Current report | SEC |
All 137 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 16, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 26, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 26, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 11, 2026 | Results | SEC |
| 8-K · Current report | Feb 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Nov 5, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 24, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 17, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 17, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 7, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13D · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Oct 17, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| SEC STAFF LETTER | Oct 17, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Oct 11, 2024 | Offer document | SEC |
| 424B4 · Prospectus | Oct 11, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 11, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| S-1MEF · Registration of more shares for the same offering | Oct 10, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Oct 10, 2024 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Oct 10, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Oct 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 8, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Oct 7, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 18, 2024 | Other filings | SEC |
| S-1 · Registration statement | Sep 18, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 20, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Aug 9, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Aug 9, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 25, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jul 18, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jul 18, 2024 | Offer document | SEC |
| SEC STAFF LETTER | Jul 16, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 9, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Jun 12, 2024 | Offer document | SEC |
Cap table
Built by 6ix from Upstream Bio, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 54,811,391
- Fully diluted
- 54,811,391
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 54,811,391 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 54,811,391 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Daniella Beckman Other companies: Blueprint Medicines Corp (Director · Since at least Dec 8, 2021); Tango Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 10, 2021); Vor Biopharma Inc. (Chair of the Audit Committee · Since at least Feb 4, 2021); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Translate Bio Inc (Director · Jun 18, 2019 – Sep 14, 2021 · Past) | Member, Board of Directors · Since at least Oct 10, 2024 |
| Michael Gray Other companies: POINT Biopharma Global Inc (Director · Jul 7, 2020 – Jul 7, 2020 · Past); Enliven Therapeutics, Inc. (CFO & COO · Mar 11, 2020 – Feb 22, 2023 · Past); X4 Pharmaceuticals, Inc. (President, CEO and CFO, Director · Nov 15, 2017 – Nov 27, 2018 · Past) | CFO and COO · Since at least Oct 10, 2024 |
| Harold Edward Fleming Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); CRISPR Therapeutics AG (Director · Since at least Jun 10, 2021) | Director · Since at least Oct 10, 2024 |
| Marcella Kuhlman Ruddy Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Tectonic Therapeutic, Inc. (Chief Medical Officer · Since at least Jun 20, 2024) | Chief Medical Officer, Tectonic Therapeutic · Since at least Oct 10, 2024 |
| Edd Fleming Other companies: Sionna Therapeutics, Inc. (Director · Since at least Nov 5, 2026) | Executive Vice President, Enavate Sciences · Since at least Nov 5, 2026 |
| Aaron Deykin | Chief Medical Officer & Head of R&D · Since at least Jun 16, 2026 |
| Adam Houghton | Chief Business Officer · Since at least Jun 16, 2026 |
| Allison Ambrose | General Counsel · Since at least Dec 16, 2024 |
| Amy Iannelli | Vice President, Finance · Since at least Nov 5, 2026 |
| Ashish Kalra | Vice President, Translational Research · Since at least Jun 5, 2025 |
All 22 people
| Person | Seat |
|---|---|
| Christopher Silva | Vice President, Supply Chain · Since at least Nov 5, 2026 |
| Ken Adams | Senior Vice President, Clinical Operations & Medical Writing · Since at least Nov 4, 2026 |
| Liam Ratcliffe | Head of Biotechnology, Access Industries · Since at least Nov 5, 2026 |
| Marie Sanchirico | Vice President, Medical Affairs · Since at least Nov 5, 2026 |
| Meggan Buckwell | Director, Corporate Communications and Investor Relations · Since at least Mar 1, 2026 |
| Mersedeh Miraliakbari | Senior Vice President, Regulatory Affairs and Quality · Since at least Nov 5, 2026 |
| Mike Gray | Chief Financial Officer and Chief Operating Officer · Since at least Sep 17, 2026 |
| Parika Petaipimol | Vice President, Technical Operations · Since at least Nov 5, 2026 |
| Rand Sutherland | Chief Executive Officer · Since at least Aug 11, 2026 |
| Ron Renaud | Chair, Board of Directors · Since at least Nov 4, 2026 |
| Stacy Price | Chief Technology Officer · Since at least May 20, 2025 |
| Sumathi Sivapalasingam | Vice President & Head of Clinical Development · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Upstream Bio, Inc.